Is Dogwood Therapeutics profitable?

Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.

What is Dogwood Therapeutics's earnings per share?

Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.

Where does Dogwood Therapeutics's income statement data come from?

Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Dogwood Therapeutics DWTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Rental income	——	——	——	——	——
Research and development	$22.1M+1.1%	$21.87M+0.1%	$21.84M+178%	$7.86M+39.7%	$5.62M+59.3%
General and administrative	$6.52M+6.8%	$6.1M-38.1%	$9.86M-4.6%	$10.34M+6.4%	$9.72M+11.8%
Other operating expenses	$28.61M+2.3%	$27.97M-11.8%	$31.7M+74.2%	$18.2M+18.6%	$15.34M+25.5%
Total operating expenses	$28.61M+2.3%	$27.97M-11.8%	$31.7M+74.2%	$18.2M+18.6%	$15.34M+25.5%
Operating income	-$28.61M-2.3%	-$27.97M+11.8%	-$31.7M-74.2%	-$18.2M-18.6%	-$15.34M-25.5%
Interest expense	$321.38K+232%	$96.94K+188%	-$110.57K+35.2%	-$170.66K+34.9%	-$262.05K-184%
Other income (expense), net	$269.93K+104%	-$6.13M+3.0%	-$6.31M+0.7%	-$6.35M+1.5%	-$6.45M-5,145%
Gain (loss) on extinguishment of debt	——	——	——	——	——
Gain (loss) on disposal of assets	——	-$2.73K—	——	——	——
Income before income taxes	-$28.29M+16.9%	-$34.04M+10.5%	-$38.02M-54.8%	-$24.55M-12.7%	-$21.79M-76.5%
Net income	-$28.32M+17.3%	-$34.26M+10.3%	-$38.2M-54.4%	-$24.74M-12.5%	-$21.98M-78.0%
Diluted earnings per share	——	——	-$26.21-30.7%	-$20.06-4.4%	-$19.22-54.4%
Basic earnings per share	——	——	-$26.21-30.7%	-$20.06-4.4%	-$19.22-54.4%
Weighted-average shares, diluted	42.4M+313%	10.2M+62.7%	6.3M+14.7%	5.5M+22.1%	4.5M+17.6%
Weighted-average shares, basic	42.4M+313%	10.2M+62.7%	6.3M+14.7%	5.5M+22.1%	4.5M+17.6%
Interest Income (Expense), Nonoperating	$321.38K+232%	$96.94K+188%	-$110.57K+35.2%	-$170.66K+34.9%	-$262.05K-184%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$26.24M+15.3%	-$30.98M+22.2%	-$39.84M-59.3%	-$25.01M+3.0%	-$25.79M-59.0%
Deferred taxes	$31.75K-85.6%	$221.1K+17.1%	$188.75K-0.8%	$190.19K+0.1%	$190.04K+37,881%
Gain (Loss), Foreign Currency Transaction, before Tax	——	——	-$43.95K-28.7%	-$34.14K+26.4%	-$46.36K-50.6%
Gain Loss On Sale Of Property Plant Equipment	——	-$2.73K—	——	——	——
Other income, net (Note 6)	$269.93K+104%	-$6.13M+3.0%	-$6.31M+0.7%	-$6.35M+1.5%	-$6.45M-5,145%
Temporary Equity Accrual Of Paid In Kind Dividends	——	——	——	——	-$1.64M-219%
EBIT	-$28.61M-2.3%	-$27.97M+11.8%	-$31.7M-74.2%	-$18.2M-18.6%	-$15.34M-25.5%
EBITDA	——	——	——	-$18.16M-18.5%	-$15.32M-25.4%
EBIT	-$28.61M-2.3%	-$27.97M+11.8%	-$31.7M-74.2%	-$18.2M-18.6%	-$15.34M-25.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Dogwood Therapeutics profitable?: Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.
What is Dogwood Therapeutics's earnings per share?: Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.
Where does Dogwood Therapeutics's income statement data come from?: Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.